<DOC>
	<DOC>NCT00291668</DOC>
	<brief_summary>This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.</brief_summary>
	<brief_title>Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients who are diagnosed with Crohn's disease (according to the Crohn's disease diagnostic criteria developed by the research group on intractable inflammatory bowel disorders [Shimoyama group, January 25, 2002]) at least 24 weeks before the starting date of the observation period Patients with Crohn's Disease Activity Index (CDAI) score ranging from 220 to 450 inclusive during the observation period Creactive protein (CRP) of 1 mg/dL or higher in the laboratory test performed at the start of the observation period Stoma patient Patients with a history of severe hypersensitivity or anphylactic reaction to antiTNF alpha antibody Patients who participated in a clinical study with CDP870 Pregnant or lactating patients, patients of childbearing potential, or patients who will attempt pregnancy during the study period Patients who are judged inappropriate for enrollment by the principal investigator or subinvestigators</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Crohn's Disease</keyword>
	<keyword>CDP870, Certolizumab pegol</keyword>
</DOC>